Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices.

Category Primary study
JournalJournal of Clinical Oncology
Year 2006
This article has no abstract
Epistemonikos ID: 63e81ab7af474140a5ae0c1b7e138815d2dadebf
First added on: Apr 04, 2025